{"nctId":"NCT00176852","briefTitle":"Stem Cell Transplant for Hemoglobinopathy","startDateStruct":{"date":"2002-06"},"conditions":["Sickle Cell Disease","Thalassemia","Severe Congenital Neutropenia","Diamond-Blackfan Anemia","Shwachman-Diamond Syndrome"],"count":22,"armGroups":[{"label":"RIC Bu/Flu (A) (discontinued)","type":"OTHER","interventionNames":["Drug: Busulfan, Fludarabine, ATG, TLI"]},{"label":"MA Bu/Cy (B)","type":"EXPERIMENTAL","interventionNames":["Drug: Busulfan, Cyclophosphamide, ATG, GCSF","Radiation: Total Body Irradiation","Procedure: Stem cell infusion"]},{"label":"RIC Cy/Flu/TBI (A2)","type":"EXPERIMENTAL","interventionNames":["Drug: Campath, Fludarabine, Cyclophosphamide","Radiation: Total Body Irradiation","Procedure: Stem cell infusion"]}],"interventions":[{"name":"Busulfan, Fludarabine, ATG, TLI","otherNames":["Busulfex","Fludara","ATG","Total lymphoid Irradiation"]},{"name":"Busulfan, Cyclophosphamide, ATG, GCSF","otherNames":["Busulfex","Cytoxan","antithymocyte globulin","granulocyte colony-stimulating factor"]},{"name":"Campath, Fludarabine, Cyclophosphamide","otherNames":["Fludara","alemtuzumab","Cytoxan"]},{"name":"Total Body Irradiation","otherNames":["TBI"]},{"name":"Stem cell infusion","otherNames":["bone marrow transplant"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with Sickle Cell Disease/Thalassemia (SCD/THAL) 0-50 years of age with an acceptable stem cell donor and disease characteristic defined by the following:\n\n  * Stroke, central nervous system (CNS) hemorrhage or a neurologic event lasting longer than 24 hours, or abnormal cerebral magnetic resonance imaging (MRI) or cerebral arteriogram or MRI angiographic study and impaired neuropsychological testing\n  * Acute chest syndrome with a history of recurrent hospitalizations or exchange transfusions\n  * Recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more years or recurrent priapism,\n  * Impaired neuropsychological function and abnormal cerebral MRI scan\n  * Stage I or II sickle lung disease,\n  * Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate \\[GFR\\] 30-50% of the predicted normal value)\n  * Bilateral proliferative retinopathy and major visual impairment in at least one eye\n  * Osteonecrosis of multiple joints with documented destructive changes\n  * Requirement for chronic transfusions but with red blood cell (RBC) alloimmunization \\>2 antibodies during long term transfusion therapy\n* Patients with transfusion dependent alpha- or beta-thalassemia 0-35 years of age with an acceptable stem cell donor as defined in the criteria in section above.\n* Patients with other non-malignant hematologic disorders that are transfusion-dependent or involve other potentially life-threatening cytopenias (including but not limited to Severe Congenital Neutropenia, Diamond-Blackfan Anemia and Shwachman-Diamond Syndrome) who are 0-35 years of age with an acceptable stem cell donor\n* Second Transplants\n\n  * Patients with sickle cell disease or thalassemia who have failed to engraft or have autologous recovery after a myeloablative SCT regimen or non-myeloablative regimen are eligible for this protocol.\n  * Regimen A2 will be utilized for patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or for any patient who has pre-existing organ dysfunction making them ineligible for a myeloablative preparative regimen.\n  * Regimen B will be utilized for patients with sickle cell disease or thalassemia who have an HLA-identical sibling donor.\n  * Patients must meet above criteria.\n  * If the patient has received prior radiation therapy, eligibility to receive additional radiation therapy must be determined by Dr. Dusenbery\n  * If first transplant was a non-myeloablative regimen, the second transplant can occur at any time\n  * If the first transplant was a myeloablative regimen, then the second transplant must be \\> 6 months from the first transplant\n\nExclusion Criteria:\n\n* Patients with one or more of the following:\n* Karnofsky or Lansky performance score \\<70\n* Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy\n* Stage III-IV lung disease\n* GFR\\<30% predicted\n* Pregnant or lactating females\n* Active serious infection whereby patient has been on intravenous antibiotics for one week prior to study entry. Any patient with AIDS or ARC or HIV seropositivity\n* Psychologically incapable of undergoing bone marrow transplant (BMT) with associated strict isolation or documented history of medical non-compliance\n* Patients not able to receive total lymphocytic irradiation (TLI) due to prior radiation therapy","healthyVolunteers":false,"sex":"ALL","maximumAge":"50 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity","description":"In general, grade 3 equates to moderate, grade 4 to severe and grade 5 to death.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Chimerism at 100 Days","description":"The number of patients whose blood and/or bone marrow contains \\> 10% donor cells.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Chimerism at 6 Months","description":"The number of patients whose blood and/or bone marrow contains \\> 10% donor cells.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Chimerism at 1 Year","description":"The number of patients whose blood and/or bone marrow contains \\> 10% donor cells.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Grade 2-4 Acute Graft Versus Host Disease (Acute GVHD)","description":"The number of patients who experienced grades 2-4 Acute GVHD. Acute GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Grades 2-4 equate to mild to severe disease. Symptoms typically appear within weeks after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Grade 3-4 Acute Graft Versus Host Disease (Acute GVHD)","description":"The number of patients who experienced grades 3-4 Acute GVHD. Acute GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. IGrades 3-4 equate to moderate to severe disease. Symptoms typically appear within weeks after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)","description":"The number of patients who experienced Chronic GVHD. Chronic GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)","description":"The number of patients who experienced Chronic GVHD. Chronic GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment","description":"The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is \"perfect\" health and 0 is death.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment","description":"The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is \"perfect\" health and 0 is death.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment","description":"The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is \"perfect\" health and 0 is death.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Determine Physical Characteristics and Biologic Effects of Mixed Populations of Donor and Host Red Blood Cells","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Determine the Concentration of Campath in the Serum","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Overall Survival","description":"Number of patients alive 100 days after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Number of patients alive 1 year after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Free Survival","description":"Number of patients alive without disease 100 days after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Free Survival","description":"Number of patients alive without disease 1 year after transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":3},"commonTop":["Hypertension","Bacterial Infection, Blood","Pneumonia","Viral Infection, Pulmonary","Viral Infection, Gastrointestinal"]}}}